| Date | Title | Description |
| 27.04.2026 | Ray Therapeutics Secures $125M for Advanced Vision Restoration Therapies | Ray Therapeutics closed an oversubscribed $125M Series B. The funding propels advanced optogenetic vision restoration therapies. Janus Henderson Investors led the round. Capital supports clinical development for RTx-015 (Retinitis Pigmentos... |
| 21.04.2026 | Ray Therapeutics: $125 Million Series B Raised For Vision Restoration Therapies | Ray Therapeutics announced the closing of an upsized and oversubscribed $125 million Series B financing round to advance its vision-restoration treatments. The round was led by Janus Henderson Investors, with participation from new investor... |
| 21.04.2026 | Ray Therapeutics shines a light on $125M round targeting genetic eye therapy | Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.
The oversubscribed round was led by Janus He... |
| 21.04.2026 | Ray Therapeutics Raises $125M in Series B Funding | Ray Therapeutics, a Berkeley, CA-based clinical-stage biopharmaceutical company developing differentiated vision restoration therapies for those living with retinal degenerations, raised $125M in Series B funding.
The round was led by Janus... |
| 25.04.2025 | Ray Therapeutics: $8 Million CIRM Grant Awarded | Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM). This grant will suppor... |
| 19.11.2024 | C Ray Therapeutics: A New Dawn in Radiopharmaceuticals | In the bustling landscape of biotechnology, C Ray Therapeutics has emerged as a beacon of innovation. This Chengdu-based startup recently completed a Series A+ funding round, raising over $100 million. The investment was co-led by Shenzhen ... |
| 18.11.2024 | C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital | CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion o... |
| 18.11.2024 | C Ray Therapeutics Completes Over $100M Series A+ Financing | C Ray Therapeutics, a Chengdu, China-based enterprise in the field of radiopharmaceuticals, raised over $100M in Series A+ funding.
The round was led by Shenzhen Capital Group Co., Ltd.’s Manufacturing Transformation and Upgrading New Mater... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry.
While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 13.11.2023 | Ray Therapeutics Receives $4M Grant | Ray Therapeutics, a San Francisco, CA-based optogenetics company, received a $4M grant.
California Institute for Regenerative Medicine awarded the grant.
The company intends to use the funds to support development of RTx-021, an optogenetic... |
| 13.11.2023 | Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy | Age-related macular degeneration (AMD) is a prevalent cause of vision loss among individuals over the age of 65 globally. Over 18 million people in the United States alone are estimated to have milder forms of AMD, with a substantial portio... |
| 02.06.2023 | Ray Therapeutics: Leading Optogenetics Company Secures $100 Million | Ray Therapeutics – a leading optogenetics company – announced an upsized oversubscribed $100 million Series A financing round led by Novo Holdings A/S and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund... |
| 18.05.2023 | 4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing | - Ray Therapeutics Closes Oversubscribed $100M Series A Financing |
| 16.05.2023 | Ray Therapeutics Closes $100M Series A Financing | Ray Therapeutics, a San Francisco, CA-based optogenetics company, raised $100M in Series A funding.
The round was led by Novo Holdings A/S, and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, and exist... |
| 16.05.2023 | Ray Therapeutics Raises $100M Series A |
SAN FRANCISCO, CA, Ray Therapeutics, a leading optogenetics company, today announced an upsized and oversubscribed $100 million Series A financing round.
>> Click here for more funding data on Ray Therapeutics
>> To export R... |
| 12.05.2022 | Ray Therapeutics Receives $4M in Funding from the California Institute for Regenerative Medicine | 27 April 2022 |
| 26.04.2022 | Ray Therapeutics is awarded $4M in funding from CIRM to support development of their platform | - |
| 04.01.2022 | Will Silicon Valley finally change after the Elizabeth Holmes verdict? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
After a four-month-long trial, Elizabeth Holmes of the now-defunct blood testing startup Theranos... |
| 04.01.2022 | Ray Therapeutics Lands $6M Seed Round |
SAN DIEGO, CA, Ray Therapeutics today announced the closing of a $6 million seed financing round, led by 4BIO Capital.
>> Click here for more funding data on Ray Therapeutics
>> To export Ray Therapeutics funding data to PDF... |
| 04.01.2022 | 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics | Press Release
4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics
4 January 2022
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector,... |
| 04.01.2022 | Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseases | Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.
The funding will be used to advance its optogenet... |
| 04.01.2022 | Ray Therapeutics Raises $6M in Seed Funding | Ray Therapeutics, a San Diego CA-based biotech company, raised $6M in Seed funding.
The round was led by 4BIO Capital.
The company intends to use the funds to advance its lead optogenetics gene therapy Ray-001 into clinical trials for retin... |
| 04.01.2022 | 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics | Press Release
4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics
4 January 2022
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector,... |
| 04.01.2022 | Ray Therapeutics raised $6M in seed funding to advance ontogenetic therapies | - |
| - | Optogenetic Gene Therapy Company Ray Therapeutics Awarded $4 Million Grant | Ray Therapeutics recently announced it raised $4 million. These are the details.
Ray Therapeutics – a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions – announced that the Califor... |
| - | 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has led a $6 million seed financing round in Ray Therapeutics (or “th... |
| - | Ray Therapeutics | “Ray Therapeutics – Vision, Reimagined.” |
| - | Ray Therapeutics | “Ray Therapeutics' mission is to restore vision in patients with retinitis pigmentosa and other degenerative retinal disorders with our novel optogenetics approach.” |
| - | Ray Therapeutics Raises $6 Million In Seed Funding | Ray Therapeutics recently announced it raised $6 million in a seed round of funding. These are the details.
Ray Therapeutics — a biotech company developing optogenetic gene therapies for patients with blinding diseases — recently announced ... |
